Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Farber, R. Frantz, R. Schilz, M. Chakinala, B. Hartline, D. Miller, D. Rosenberg, W. Benton, R. Barst (Boston, Rochester, Cleveland, St. Louis, South San Francisco, San Francisco, New York, United States Of America; Allschwil, Swaziland). Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT. Eur Respir J 2013; 42: Suppl. 57, 3409

Member's Comments

No comment yet.

Related content which might interest you: Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Pulmonary artery dissection (PAD) in a patient with diffuse interstitial lung disease and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Pregnancy and pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Prevalence of relapses and chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015